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AbstrAct
Purpose: Non-small-cell lung cancers harboring EML4-ALK rearrangements are 
sensitive to crizotinib. However, despite initial response, most patients will eventually 
relapse, and monitoring EML4-ALK rearrangements over the course of treatment may 
help identify these patients. However, challenges associated with serial tumor biopsies 
have highlighted the need for blood-based assays for the monitoring of biomarkers. 
Platelets can sequester RNA released by tumor cells and are thus an attractive source 
for the non-invasive assessment of biomarkers. Methods: EML4-ALK rearrangements 
were analyzed by RT-PCR in platelets and plasma isolated from blood obtained from 
77 patients with non-small-cell lung cancer, 38 of whom had EML4-ALK-rearranged 
tumors. In a subset of 29 patients with EML4-ALK-rearranged tumors who were 
treated with crizotinib, EML4-ALK rearrangements in platelets were correlated with 
progression-free and overall survival. Results: RT-PCR demonstrated 65% sensitivity 
and 100% specificity for the detection of EML4-ALK rearrangements in platelets. In 
the subset of 29 patients treated with crizotinib, progression-free survival was 3.7 
months for patients with EML4-ALK+ platelets and 16 months for those with EML4-
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INtrODUctION
Cancers driven by genetic alterations are likely to 
be sensitive to therapeutic inhibitors targeting the mutated 
pathway. For example, causative epidermal growth factor 
receptor (EGFR) mutations, present in approximately 
16% of non-small-cell lung cancers (NSCLC), confer 
sensitivity to the EGFR tyrosine kinase inhibitors (TKIs) 
gefitinib, erlotinib and afatinib [1-3]. Rearrangements in 
the anaplastic lymphoma kinase (ALK) gene, occurring in 
2-7% of NSCLC, also define a distinct molecular subtype 
of lung cancer [4]. The most common ALK rearrangement 
is an inversion that juxtaposes echinoderm microtubule-
associated protein-like 4 (EML4) with ALK and produces 
the aberrant EML4-ALK fusion gene, with multiple 
chimeric variants, all of which encode the same portion 
of ALK but contain different truncations of EML4 [4]. 
ALK-rearranged tumors depend on ALK for growth and 
survival and show marked sensitivity to ALK inhibitors 
such as crizotinib, ceritinib, and alectinib [5-8]. However, 
despite initial responses, acquired resistance to these 
targeted therapies invariably leads to disease progression. 
Approximately one-third of patients with ALK-
rearranged NSCLC relapse due to an acquired mutation 
within the ALK tyrosine kinase domain [9]. EML4-ALK 
amplification and bypass signaling, that re-establish 
activation of key downstream proliferation and survival 
signals despite inhibition of the original oncogene, are 
alternative mechanisms of resistance [10]. 
The assessment of biomarkers of resistance can 
facilitate the early identification of patients likely to 
relapse, ideally before radiographic imaging provides 
evidence of progression. However, while testing biopsied 
tumor tissue remains the current recommended method for 
mutation analysis, challenges associated with serial tumor 
biopsying, particularly in NSCLC, have spurred the search 
for non-invasive blood-based assays to allow frequent 
assessment of biomarkers as part of routine clinical care. 
Tumor cells can release RNA into the blood by a variety 
of microvesicle-dependent or -independent mechanisms, 
and several models have shown that platelets are crucial 
to tumor cell growth, spread, invasion, intravasation, 
migration, extravasation, and establishment of distant 
metastasis [11-13]. Using confocal microscopy and reverse 
transcription-polymerase chain reaction (RT-PCR), we 
have previously shown that platelets isolated from healthy 
individuals take up RNA-containing membrane vesicles 
from cancer cells [14]. Moreover, platelets isolated from 
patients with glioma and prostate cancer contained the 
cancer-associated RNA biomarkers EGFRvIII and prostate 
cancer antigen 3 (PCA3), respectively [14]. Since platelet 
RNA can be readily isolated and analyzed, platelets seem 
to be an attractive source for the non-invasive monitoring 
of biomarkers [15, 16]. However, to the best of our 
knowledge, the use of platelets to detect EML4-ALK 
rearrangements in patients with NSCLC has not yet been 
investigated. 
We have assessed the feasibility of detecting EML4-
ALK rearrangements in platelets and plasma from patients 
with NSCLC, with and without EML4-ALK-rearranged 
tumors, and from healthy controls. In addition, in a subset 
of patients treated with crizotinib we have examined 
the potential impact of EML4-ALK rearrangements in 
platelets on outcome. We have also monitored EML4-
ALK rearrangements in platelets from one index patient 
throughout the course of treatment. 
rEsULts
Detection of EML4-ALK rearrangements in 
platelets and plasma of NscLc patients
This study was designed with three parallel 
objectives: firstly, to determine the sensitivity and 
specificity of detecting EML4-ALK rearrangements in 
platelets and plasma, correlated with matched tissue 
biopsies; secondly, to examine the potential impact of the 
EML4-ALK rearrangement in platelets on outcome to 
crizotinib; thirdly, to test the feasibility of monitoring a 
patient throughout treatment based on assessment of the 
EML4-ALK rearrangement in platelets.
For the first objective, blood samples from 77 
patients diagnosed with NSCLC between 2008 and 2014 
were collected from public hospitals in The Netherlands 
(n = 49), Spain (n = 25), and the United States (n = 3). 
Thirty-eight patients had EML4-ALK-rearranged tumors, 
detected by fluorescence in situ hybridization (FISH), 
RT-PCR, or both (Figure 1A). Patient characteristics are 
shown in Supplementary Table 1. Thirty-five of these 
38 patients received crizotinib - nine as first-line, 13 as 
second-line, and 13 as further lines of treatment - attaining 
an overall response rate (ORR) of 66% and median 
progression-free survival (PFS) of seven months (95% 
CI, 3.8 to 10.2). 
ALK− platelets (hazard ratio, 3.5; P = 0.02). Monitoring of EML4-ALK rearrangements 
in the platelets of one patient over a period of 30 months revealed crizotinib resistance 
two months prior to radiographic disease progression. Conclusions: Platelets are a 
valuable source for the non-invasive detection of EML4-ALK rearrangements and may 
prove useful for predicting and monitoring outcome to crizotinib, thereby improving 
clinical decisions based on radiographic imaging alone.
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Table 1 shows the detection rate of EML4-ALK 
rearrangements in paired tissue and blood samples. 
Plasma RNA was isolated from the blood samples of 32 
patients, 14 of whom had EML4-ALK-rearranged tumors. 
EML4-ALK rearrangements were detected in plasma of 
three patients with EML4-ALK-rearranged tumors and 
in none of those without EML4-ALK rearrangements 
in their tumors, indicating 21% sensitivity and 100% 
specificity of the RT-PCR test in plasma RNA. Platelet 
RNA was isolated from the blood samples of 67 patients, 
34 of whom had EML4-ALK-rearranged tumors. EML4-
ALK rearrangements were detected in the platelets of 22 
patients with EML4-ALK-rearranged tumors and in none 
of those without EML4-ALK rearrangements in tumor, 
indicating 65% sensitivity and 100% specificity of the RT-
PCR test in platelet RNA. EML4-ALK rearrangements 
were not detected in platelets from any of the 21 healthy 
donors (Table 1). 
table 1: Detection of EML4-ALK rearrangements by rt-Pcr in plasma and platelets from 77 NscLc patients and 
21 healthy controls
EML4-ALK rearrangement 
detected in Plasma
EML4-ALK 
rearrangement detected 
in Platelets
NSCLC patients N = 32* N = 67*
   EML4-ALK-rearranged tumor 3/14 22/34
   EML4-ALK rearrangement not detected in 
tumor 0/18 0/33
Healthy controls nd 0/21
Sensitivity 21% 65%
Specificity 100% 100%
Accuracy 66% 86%
nd, not determined
*Plasma and platelets were isolated in 32 and 67 samples respectively.
Figure 1: A. A representative EML4-ALK positive case by FISH in tissue and by RT-PCR in platelets (visual (left)- and quantitative 
(right)- analysis). Analyzed platelet samples were confirmed by Sanger sequencing of the RT-PCR products. The NSCLC human cell line 
H3122 served as positive control (PC). NC, negative control. b. Uptake of tumor-derived EML4-ALK RNA in platelets. Labeled exosome 
uptake in platelets, exosomes from the H2228 NSCLC cell line were labeled with PKH67. The exosome uptake into platelets was visualized 
as overlapping PKH67 labeled exosomes and labeled phalloidin (Rhodamine) in platelets. c. Positive transfer of EML4-ALK transcripts 
from H2228 exosomes into platelets. Exo, exosomes from positive control cell line; NTC, non-template control.
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Exosomes transfer rNA to platelets
Figure 1B and 1C demonstrate that exosomes 
released by cancer cells are vehicles capable of transferring 
tumor-derived EML4-ALK rearranged RNA into platelets, 
as shown by confocal microscopy and RT-PCR. Platelets 
were isolated from healthy donors and exosomes were 
isolated from H2228 EML4-ALK+ NSCLC cells. Isolated 
exosomes were labelled with PKH67 green fluorescent 
dye and subsequently incubated with the blood platelets. 
Confocal microscopy was used to confirm that the 
PKH67-labeled exosomes derived from H2228 NSCLC 
cells were internalized by the platelets (Figure 1B). RT-
PCR was used to establish exosome-mediated transfer of 
tumor-derived EML4-ALK rearranged RNA from cancer 
cells to blood platelets. EML4-ALK RNA was detected by 
RT-PCR in platelets that were incubated with exosomes 
isolated from H2228 NSCLC cells and not in platelets 
incubated with exosomes from A549, an EML4-ALK − 
NSCLC cell line (Figure 1C).
EML4-ALK rearrangements in platelets and 
outcome to crizotinib
Of the 35 crizotinib-treated patients, six had blood 
samples obtained at the time of progression only and were 
not included in the survival analyses, while 29 had blood 
samples obtained at baseline and/or during treatment 
before progression and were included in the analyses of 
PFS, overall survival and response. Median age of the 29 
patients was 57 years (range, 37-81); 16 were never or 
former smokers; 24 had performance status (PS) 0-1; six 
had brain metastases (Supplementary Table 1).
Twenty-three of the 29 patients had only one 
blood sample available; six patients had two samples, 
obtained at baseline and during treatment. The EML4-
ALK rearrangement was detected in platelets of 14 of 
the 23 patients with only one sample. These 14 patients 
were classified as EML4-ALK+, while the remaining 
nine were classified as EML4-ALK−. Of the six patients 
with two blood samples available, three had EML4-ALK 
rearrangement detected at baseline, but lost it during 
treatment and therefore classified as EML4-ALK−, for one 
Figure 2: Flowchart showing the distribution of patients in the study. Seventy-seven patients with NSCLC were included in 
the study testing the feasibility of detecting EML4-ALK rearrangements in platelets. A subset of 29 patients was included in the analysis of 
outcome according to EML4-ALK status in platelets.
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case it was the reverse where EML4-ALK could be found 
during treatment, hence classified as EML4-ALK+. The 
remaining two samples were negative at both occasions. A 
total of 15 patients were classified as EML4-ALK+ and 14 
as EML4-ALK− (Figure 2 and Supplementary Table S2). 
With a median follow-up of 13 months (range one 
to 48), PFS for all 29 crizotinib-treated patients was 7.0 
months (95% confidence intervals [CI], 4.4 to 14.7), while 
it was 16 months (95% CI, 5.0 to not reached [NR]) for 
the 14 EML4-ALK− patients and 3.7 months (95% CI, 
1.1 to 8.7) for the 15 EML4-ALK+ patients (P = 0.01) 
(Figure 3A). In the univariate analysis of PFS - including 
sex, age, PS, brain metastasis, number of previous lines of 
treatment, and EML4-ALK rearrangements in platelets - 
only EML4-ALK+ status was associated with shorter PFS 
(hazard ratio [HR], 3.5; 95% CI, 1.2 to 10.1; P = 0.02) 
(Figure 3A; Supplementary Table S3). 
Median overall survival was NR (95% CI, 6.4 to 
NR) for all 29 crizotinib-treated patients, while it was 
NR (95% CI, 8.0 to NR) for the 14 EML4-ALK− patients 
and 6.7 months (95% CI, 2.3 to NR) for the 15 EML4-
ALK+ patients (HR, 3.0; 95% CI, 0.8 to 11.7; P = 0.11) 
(Figure 3B). No variable was identified as a marker of 
overall survival in the univariate analysis (Supplementary 
Table S3). No significant differences in crizotinib response 
were observed between EML4-ALK+ and EML4-ALK− 
patients (Supplementary Table S4).
serial monitoring of EML4-ALK rearrangements 
in platelets of one representative patient
In order to test our hypothesis that the emergence 
of acquired resistance can be detected non-invasively 
in platelets before radiographic evidence of disease 
progression, we monitored a 37-year-old female non-
smoker with NSCLC. EML4-ALK v1 was detected in 
her tumor and platelets at baseline in March 2012 (Figure 
3C). She responded to crizotinib treatment and the EML4-
ALK rearrangement was lost in her platelets. During a 
one-month interruption of crizotinib treatment due to 
appendicitis, the EML4-ALK rearrangement was detected 
in her platelets but was lost when she reinitiated crizotinib 
treatment. In June 2014, the EML4-ALK rearrangement 
was again detected in her platelets; however, positron 
emission tomography- computed tomography (PET-CT) 
did not show disease progression until two months later, 
in August 2014 (Figure 3C). 
DIscUssION
In the present study, we have examined the use of 
platelets and plasma for the non-invasive assessment of 
EML4-ALK rearrangements and found that platelets 
are a promising biosource. Moreover, the detection 
and persistence of EML4-ALK rearrangement in 
platelets was significantly associated with shorter PFS 
to crizotinib. Interestingly, in the index patient, the 
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Figure 3: Kaplan-Meier estimates of A. PFS and b. overall survival according to status of the EML4-ALK rearrangement in platelets 
for 29 crizotinib-treated NSCLC patients. Tick marks on the survival curves indicate censored data. c. Longitudinal monitoring of crizotinib 
response in an index patient. Platelet EML4-ALK status was confirmed (shown to the left) at time points indicated by vials depicted above 
and radiological response depicted below corresponding to the time points represented by letter A-E. During one month rest from crizotinib 
due to appendicitis, EML4-ALK returned in platelets until the patient was back on crizotinib treatment. The EML4-ALK transcript was 
detected in platelets two months prior to radiographic disease progression. NC, negative control; PC, positive control; PR, Partial response; 
PD, Progressive disease; CT, computed tomography; PET, positron emission tomography
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re-appearance of the EML4-ALK rearrangement in 
platelets predicted resistance to crizotinib two months 
before radiographic progression. Platelets therefore can 
be considered alongside other promising biosources, 
like plasma, exosomes, circulating-free DNA and 
circulating tumor cells (CTCs), all of which have been 
proposed as alternative platforms for biomarker analysis 
(Supplementary Figure S1) [17-19]. In addition, Klement 
et al. have previously demonstrated selective uptake of 
tumor derived protein biomarkers in platelets [20, 21]. 
In the present study, plasma RNA had lower 
sensitivity than platelets (21% vs 65%) for the detection 
of EML4-ALK rearrangements by RT-PCR. The lower 
sensitivity in plasma may be attributed to a rapid 
degradation of free-circulating RNA molecules or low 
abundance of free-circulating exosomes containing 
rearranged EML4-ALK. Several groups have used CTCs 
for detection of biomarkers [22]. For example, Pailler et 
al., examined ALK rearrangements in CTCs of NSCLC 
patients and found four or more ALK-rearranged CTCs 
per 1 ml of blood, with 100% sensitivity and specificity 
[17]. Nevertheless, since CTCs typically constitute 
of a few cancer cell per tens of millions of normal 
nucleated cells in the blood, their use for the detection 
of EML4-ALK rearrangements must rely on novel 
CTC detection strategies. Circulating-free DNA has 
limitations when it comes to large rearrangements, since 
finding the chromosomal brake-point needs extensive 
deep sequencing of the genomic DNA. Unfortunately, 
platelets are not yet stored routinely and prospective 
collection is often required to analyze platelet RNA. 
Another disadvantage of blood platelets could be their 
potential reaction towards certain therapies, resulting in 
reduced platelet counts in the blood and potential platelet 
activation. However, in direct comparison with the other 
liquid biosources for the detection and monitoring of 
EML4-ALK rearrangements, platelets are a valid and 
competitive biosource when it comes both to detection and 
response to therapy, as well as ease of extraction and rapid 
readout of the assays. The utility of our EML4-ALK test 
in therapy monitoring was illustrated in our index patient 
from whom we monitored EML4-ALK rearrangements in 
platelets throughout the course of her treatment. This index 
case exemplifies the use of serial monitoring of EML4-
ALK rearrangements in platelets to predict progression, 
thereby providing physicians with an early window of 
opportunity to modify treatment and switch to a second-
generation ALK inhibitor, such as ceritinib or alectinib.
EML4-ALK rearrangements in platelets are a 
direct readout of the effect of crizotinib on EML4-ALK-
rearranged NSCLC cells. Adequate crizotinib-mediated 
cell eradication results in reduced release of EML4-
ALK transcripts into circulation, and hence the loss of 
platelet EML4-ALK transcripts. By contrast, crizotinib 
resistance causes continuous production and release of 
EML4-ALK transcripts. The source of DNA in the blood 
of cancer patients are cells that disintegrate by apoptosis 
and/or necrosis in expanding tumor tissue [23]. In contrast 
RNA released into the blood by microvesicle-dependent 
or -independent mechanisms is functionally active in 
recipient cells, suggesting that tumor cells can exploit 
circulating RNA as a means to ‘communicate’ with 
their regional or distal environment [24]. Therefore, an 
expressed biomarker (e.g. EML4-ALK RNA molecules) 
will tell us more about cellular dysfunctions than 
biomarkers derived from apoptotic or necrotic cells (e.g. 
fragmented DNA). This further supports non-invasive 
RNA based blood tests for the monitoring of ongoing 
alterations within the tumor while responding to therapy. 
Although patients in our study with EML4-ALK+ 
platelets had dismal prognosis, our finding can also lead 
to potentially beneficial opportunities for treatment in this 
subgroup of patients. Recruitment of platelets by tumor 
cells is regulated by signaling molecules released by the 
tumor or its metastases. One of these molecules is Aggrus/
podoplanin, a protein that attracts platelets expressing the 
CLEC-2 receptor [13]. Blocking the binding of Aggrus/
podoplanin to CLEC-2-expressing platelets could be a 
novel therapeutic approach with benefit for EML4-ALK+ 
patients.[25] ALK has recently been shown to regulate 
the production of vascular endothelial growth factor A 
(VEGFA) in anaplastic large-cell lymphoma and EML4-
ALK-rearranged NSCLC, and the anti-VEGFA antibody 
bevacizumab strongly impaired the growth of anaplastic 
large-cell lymphoma in mouse xenografts [26]. Activated 
platelets release several growth factors, including VEGF 
and, therefore, the subset of EML4-ALK+ patients could 
likely benefit from anti-angiogenic therapy [13, 26].
MAtErIALs AND MEtHODs
cell lines
The NSCLC human cell lines H3122 and H2228 
were kindly provided by Dr. Daniel Costa (Department 
of Medicine, Harvard Medical School, Boston, MA) 
and served as positive controls for the variant 1 and the 
shorter variant 3 of EML4-ALK transcript, respectively. 
The NSCLC human A549 cell line was obtained from the 
American Type Culture Collection (ATCC) collection.
Isolation of platelet and plasma rNA
Platelets and plasma were isolated from the 
same sample of whole blood in 6ml purple-cap BD 
Vacutainers containing EDTA anti-coagulant by standard 
centrifugation. The cells and aggregates were removed by 
centrifugation at room temperature for 20 min at 120g, 
resulting in platelet-rich plasma. The platelets were 
isolated from the platelet-rich plasma by centrifugation 
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at room temperature for 20 min at 360g, after which the 
plasma was centrifuged at 360g for 10 min and frozen. 
The platelet pellet was collected in 30 µl RNAlater (Life 
Technologies, Carlsbad, CA) and frozen at -80°C for 
further use. Platelets and plasma were frozen in parallel. 
Platelet RNA and plasma RNA were isolated using 
either an Agencourt Formapure (Agencourt Biosciences, 
Beverly, MA), miRvana RNA isolation kit (Life 
Technologies), or Trizol (Life Technologies), according 
to the manufacturers’ instructions. The concentration 
and quality of the platelet RNA was determined with 
an Agilent 2100 Bioanalyzer with total RNA Pico chip 
(Agilent, Santa Clara, CA). Platelet RNA of sufficient 
quality (Bioanalyzer RIN values >7 and/or distinctive 
rRNA curves) was subjected to biomarker analysis. The 
quality of plasma RNA could not be measured and only 
quantitation of RNA input was used. 
Isolation and exosome uptake
Exosomes were isolated by ultracentrifugation 
using cell culturing medium from EML4-ALK positive 
(H2228) and wild type control (A549) NSCLC cell lines. 
The medium and plasma was first cleared of debris by 
centrifugation; twice at 500xG for 10 minutes, followed 
by twice at 2,000xG for 15 minutes, and lastly twice at 
10,000xG for 30 minutes. The exosomes in the cleared 
sample were pelleted at 100,000xG for 60 minutes. The 
exosomes were washed once in PBS before either being 
labeling for uptake experiments or DNAse-I treated (4 
units; Promega) for 15min before lysis in miRVANA 
lysis buffer (Ambion) for RNA extraction (according to 
manufacturer’s recommendations) for mutation detection 
experiments. Exosome uptake was analyzed using PKH67-
labeled (Sigma-Aldrich) H2228 microvesicles and the 
LSM-710 confocal microscope system with the ZEN 2010 
software (Carl Zeiss) and a 63x oil immersion objective 
(Carl Zeiss) as previously described [14]. Platelets were 
stained with rhodamine phalloidin (Invitrogen) to indicate 
platelet structure and analyzed for exosomal uptake by 
the presence of green fluorescent dye PKH67 (Sigma-
Aldrich). EML4-ALK rearranged RNA within platelets 
was shown by PCR on reverse transcribed RNA with the 
same setup as previously described. 
rt-Pcr analysis of EML4-ALK rearrangements
At thromboDx, quantitative PCR Taqman assays 
from Life Technologies (Hs03654556, Hs03654557, and 
Hs03654558) were used for detection of the three most 
common EML4-ALK variants (v1 [e13:a20], v2 [e20:a20], 
and v3 [e6:a20], with breakpoints at EML4 exons 13, 20, 
and 6 and at ALK exon 20, respectively), according to the 
manufacturer’s instructions. Quantitative PCR was run on 
the ABI7500 (Applied Biosystems, Foster City, CA) for 60 
cycles in a standard TaqMan program with TaqMan human 
GAPDH control reagents (Life Technologies, 402869) as 
input control. EML4-ALK breakpoints were confirmed 
by Sanger sequencing of RT-PCR products, using the 
Big-Dye 1.1 sequencing kit (Applied Biosystems). At 
Pangaea Biotech, EML4-ALK was amplified by PCR and 
visualized in agarose gels. RNA was converted to cDNA 
by superscript III (Life Technologies) and amplified 
using 40 ng of cDNA and 1U Platinum Taq polymerase 
(Invitrogen) in a 20 µl reaction. Specific forward and 
reverse primers were used for the three most common 
EML4-ALK variants (Supplementary Table S5). EML4-
ALK breakpoints were confirmed by Sanger sequencing 
of RT-PCR products, using the Big-Dye 1.1 sequencing 
kit (Applied Biosystems).
statistical analyses
All participating centers sent samples in a non-
consecutive manner, and there was no stratification 
according to sex, Eastern Cooperative Oncology Group 
(ECOG) PS, smoking history, or prior treatment. PFS 
was calculated from the start of crizotinib treatment 
until first observation of disease progression by serial 
CT and/or PET-CT. Overall survival was calculated from 
the start of crizotinib treatment until death from any 
cause. Median PFS and overall survival, with their 95% 
CIs, were estimated with the Kaplan-Meier method and 
compared using the non-parametric log-rank test. The 
association between each potential prognostic factor and 
PFS or overall survival was assessed with a univariate 
Cox proportional-hazard regression model. All statistical 
analyses were performed with the use of SAS V9.3. 
Significance was set at P < 0.05.
study oversight
This study was conducted in accordance with the 
principles of the Declaration of Helsinki. Written and/or 
oral informed consent was obtained from all patients and 
documented. Approval was obtained from the institutional 
review board and the ethics committee at each hospital. 
The drug used in the study was purchased from the 
manufacturer, who had no role in the study. The data were 
collected and analyzed by the senior authors in conjunction 
with all authors. The corresponding author wrote the first 
draft of the manuscript. All the authors approved the final 
version of the manuscript, agreed with the decision to 
submit the manuscript for publication and vouched for the 
accuracy of the data and analyses reported.
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